Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0218)
| Name |
Tirapazamine
|
||||
|---|---|---|---|---|---|
| Synonyms |
TIRAPAZAMINE; 27314-97-2; 3-Aminobenzo[e][1,2,4]triazine 1,4-dioxide; 1,2,4-Benzotriazin-3-amine, 1,4-dioxide; Tirazone; 3-Amino-1,2,4-benzotriazine 1,4-dioxide; Win-59075; WIN 59075; SR 4233; SR-4233; 3-Amino-1,2,4-benzotriazine-1,4-dioxide; CHEBI:78887; SR-259075; NSC-130181; SR259075; 1,2,4-Benzotriazin-3-amine 1,4-Dioxide; 1UD32YR59G; SR259075;SR4233;Win59075; Tirapazamine [USAN:INN]; 1,2,4-benzotriazin-3-amine,1,4-dioxide; NSC 130181; BRN 0179322; UNII-1UD32YR59G; Win59075; SR4233; 4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine; TIRAPAZAMINE [MI]; Tirapazamine (USAN/INN); TIRAPAZAMINE [INN]; TIRAPAZAMINE [USAN]; SCHEMBL4048; SCHEMBL4049; 1,2,4-Benzotriazine, 3-amino-, 1,4-dioxide; TIRAPAZAMINE [MART.]; 4-26-00-01120 (Beilstein Handbook Reference); CHEMBL50882; SCHEMBL872285; TIRAPAZAMINE [WHO-DD]; Tirapazamine, >=98% (HPLC); ORYDPOVDJJZGHQ-UHFFFAOYSA-N; AMY38675; BCP03663; EX-A2967; BDBM50226806; MFCD00132954; AKOS006271584; AKOS037645846; DB04858; NCGC00390788-04; AC-31305; AS-64112; HY-13767; BCP0726000167; FT-0661586; T3823; 3-Aminobenzo[e][1,2,4]triazine1,4-dioxide; D06167; T72208; J-016728; Q3529346; 1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine; 4-hydroxy-3-imino-3,4-dihydro-1,2,4-benzotriazin-1-ium-1-olate
Click to Show/Hide
|
||||
| Status |
Phase 3
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
 |
||||
| Formula |
C7H6N4O2
|
||||
| IUPAC Name |
1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]
|
||||
| InChI |
InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
|
||||
| InChIKey |
ORYDPOVDJJZGHQ-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
| Cell migration | ||||
| In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 |
| MNNG/HOS Cl #5 cells | Osteosarcoma | Homo sapiens | CVCL_0439 | |
| U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | |
| Response regulation | SLC7A11 overexpression could restored the proliferation and migration abilities inhibited by Tirazamine. Thus, TPZ could inhibit the proliferation and migration of osteosarcoma cells, and induce ferroptosis in part through inhibiting SLC7A11. | |||